BiotechTube

VIMOVO 250/20 + VIMOVO 375/20 + VIMOVO 500/20

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Juvenile Idiopathic Arthritis (JIA)

Conditions

Juvenile Idiopathic Arthritis (JIA)

Trial Timeline

Apr 1, 2012 → Feb 1, 2015

NCT ID
NCT01544114

About VIMOVO 250/20 + VIMOVO 375/20 + VIMOVO 500/20

VIMOVO 250/20 + VIMOVO 375/20 + VIMOVO 500/20 is a approved stage product being developed by Amgen for Juvenile Idiopathic Arthritis (JIA). The current trial status is completed. This product is registered under clinical trial identifier NCT01544114. Target conditions include Juvenile Idiopathic Arthritis (JIA).

What happened to similar drugs?

0 of 20 similar drugs in Juvenile Idiopathic Arthritis (JIA) were approved

Approved (0) Terminated (2) Active (18)
🔄PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄AdalimumabEisaiPhase 3
🔄AbataceptOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01544114ApprovedCompleted

Competing Products

20 competing products in Juvenile Idiopathic Arthritis (JIA)

See all competitors
ProductCompanyStageHype Score
PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
37
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
AdalimumabEisaiPhase 3
40
AbataceptOno PharmaceuticalPhase 3
40
Ixekizumab + AdalimumabEli LillyPhase 3
44
Baricitinib + PlaceboEli LillyPhase 3
40
BaricitinibEli LillyPhase 3
47
Baricitinib + TocilizumabEli LillyPhase 3
47
adalimumab + MethotrexateAbbViePre-clinical
26
UpadacitinibAbbViePhase 1
33
Upadacitinib + TocilizumabAbbViePhase 3
47
Adalimumab + RisankizumabAbbViePhase 3
47
AdalimumabAbbViePhase 3
40
naproxen + esomeprazoleAstraZenecaPhase 1
29
Alendronate (Fosamax)MerckPre-clinical
26
canakinumabNovartisPhase 3
40
SecukinumabNovartisPhase 1
36